sh-Polypeptide-9 for Hair Regrowth
Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4
Also known as: Recombinant Human VEGF, rhVEGF, VEGF, VEGF-A, Synthetic Human VEGF, CG-VEGF, rh-Polypeptide-9
Motivation
sh-Polypeptide-9 is a lab-made copy of a human protein that tells blood vessels to sprout and to leak. Cosmetics list it for skin conditioning. Hair serums add it because vessels around a growing hair root expand during growth and shrink at rest. Adults who link hair density with healthy aging meet this peptide inside those serums.
The protein was first used to grow vessels in starved heart and limb muscle, then blocked to slow abnormal vessels in cancer and the eye. Follicle cells make the protein, a common topical hair drug raises it in a dish, and mice that overproduce it in the follicle wall regrow hair with larger shafts. The cosmetic copy has one lab test on human follicle cells beside vessel cells, with a company coauthor. No human study has counted hairs after the peptide alone.
This review examines the evidence for and against hair regrowth with this peptide, which harms are measured and which are only plausible, and how products that contain it are made and used. Cell and mouse findings stay separate from hair counts, and this peptide stays separate from multi-ingredient serums and injected mixtures.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
These pieces discuss vascular endothelial growth factor (VEGF, a protein that sprouts capillaries and makes vessels leak) in hair follicles, including the only lab study of this peptide.
- Effects of the biomimetic peptide Sh-Polypeptide 9 (CG-VEGF) on cocultures of human hair follicle dermal papilla cells and microvascular endothelial cells - Bassino et al., 2016
Only indexed test of this peptide on human follicle papilla cells (growth-steering root cells) beside vessel cells, and a coauthor worked at Rottapharm-Madaus, a commercial sponsor. It is a letter, not a clinical hair trial.
- Control of hair growth and follicle size by VEGF-mediated angiogenesis - Yano et al., 2001
Extra vessel-growth protein in the mouse follicle wall sped regrowth and enlarged shafts, and blocking it slowed growth. This is not a test of this cosmetic peptide.
- Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells - Lachgar et al., 1996
Human follicle papilla cells release this vessel-growth protein and respond by dividing and moving, and neutralizing antibodies blocked those effects. Cell work only, not a scalp trial of the cosmetic.
- Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase - Yum et al., 2017 (HIF, hypoxia-inducible factor, a low-oxygen sensor; prolyl hydroxylase, an enzyme that marks that sensor for disposal)
Shows that a common topical hair drug raises this vessel-growth protein in human follicle papilla cells by stabilizing HIF. It studies that drug, not this cosmetic peptide.
Four pieces met the bar for a direct discussion of this peptide or of VEGF in the follicle. Life Extension’s 2017 article reviews topical VEGF for skin repair and does not discuss this peptide or hair regrowth, so it is not listed. No directly relevant item was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, or Lifespan.io. Their hair and peptide material does not discuss this ingredient. Huberman’s hair episode covers scalp blood flow without naming this protein. Attia discussed the pathway only for a different peptide.
Grokipedia
No Grokipedia article on sh-Polypeptide-9 was found.
Examine
No Examine.com article on sh-Polypeptide-9 was found.
ConsumerLab
No ConsumerLab article on sh-Polypeptide-9 was found.
Systematic Reviews
No systematic reviews or meta-analyses for sh-Polypeptide-9 were found on PubMed as of September 26, 2026.
Mechanism of Action
sh-Polypeptide-9 is a recombinant copy of human vascular endothelial growth factor A (VEGF-A, the main A-form of VEGF), fermented in Escherichia coli as one chain of at most 165 amino acids. The common form, VEGF-A165, is a disulfide-linked pair of about 34–45 kilodaltons (kDa, a unit of molecular mass). Heparin binding in the tissue matrix keeps the signal local.
Vessel-lining cells bind it at VEGF receptor 2 (VEGFR-2, the site that drives new capillaries) and VEGF receptor 1 (VEGFR-1, a tighter receptor with weaker growth signals). Nitric oxide widens vessels and makes the walls leak. Mice that overproduce the protein in the follicle wall regrow hair and enlarge shafts; an antibody against it slows regrowth (Yano et al., 2001). Human papilla cells release it and divide when it is added (Lachgar et al., 1996). The only test of this peptide is a letter, with a Rottapharm-Madaus coauthor, on papilla cells beside vessel cells (Bassino et al., 2016).
After a 4-hour infusion of recombinant VEGF-A165, terminal half-life was 33.7 ± 13 minutes, with a large distribution volume from receptor and matrix binding (Eppler et al., 2002). Genentech authors had a stake in that infusion protein, and blood pressure fell. Clearance is not by cytochrome P450 enzymes (CYP enzymes, liver proteins that oxidize many small drugs); cells take the protein up and break it down. Selectivity is for VEGF receptors. Intact scalp is not expected to pass infusion-level amounts, and whether a leave-on serum reaches the papilla is unmeasured.
Historical Context & Evolution
The protein was purified in the late 1980s as a vessel-growth signal and, earlier, as a permeability factor from tumor fluid. The original aim was extra vessels in blood-starved heart and limb muscle. Infusions showed a half-life near half an hour and lower blood pressure, and the protein did not become a heart drug. Later use reversed that aim: pathway blockers became routine in several cancers and in wet macular degeneration (leaking vessels under the retina).
Hair was a side finding. Capillaries around the follicle expand in growth and recede at rest. Papilla cells make the protein and respond to it (Lachgar et al., 1996). A Pierre Fabre laboratory showed that minoxidil raises that output in culture (Lachgar et al., 1998). Mice then showed that the protein can speed regrowth and enlarge shafts, and that blocking it slows growth (Yano et al., 2001). Minoxidil also inhibits a prolyl hydroxylase (an enzyme that marks a low-oxygen sensor for disposal), one of several actions (Yum et al., 2017). They are not a trial of this peptide.
The “sh-“ mark means a synthetic human sequence sold for skin conditioning inside multi-peptide serums. Marketing borrowed the follicle papers for a hair claim. The only paper naming this peptide is an industry-linked cell letter. Minoxidil, not this peptide, has the human hair trials. Insurers rarely pay for cosmetic serums and need not cover costly injected blends, while sellers gain if the claim prevails. Standing today is the cell and mouse evidence.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no replicated human trial has measured hair count, shaft caliber, or a validated shedding score after sh-Polypeptide-9.
Medium 🟩 🟩
No benefit reaches Medium: there is no single controlled human trial and no consistent observational cohort of this peptide on a clinical hair outcome. Hair-count series of platelet preparations and of injected multi-factor blends use many signals at once and do not test sh-Polypeptide-9.
Low 🟩
Speculative 🟨
Follicle support through local vessel signaling
A lab letter tested this peptide on human follicle cells beside vessel cells. Mice making extra parent protein grew larger follicles through new vessels. No human hair-count trial of the peptide exists.
Skin conditioning ⭕️ Not Central to Hair Regrowth
This bears on skin conditioning, not hair count. Inventories list skin conditioning as the function, and supplier claims of feeding skin cells by new vessels lack a controlled trial of this peptide.
Benefit-Modifying Factors
-
Cycling follicles: The vessel story concerns follicles that still enter a growth phase. Scarring hair loss, and shedding from low iron or thyroid disease, are different problems, and this peptide has no human data there.
-
Baseline vessel supply: Thinning that is not driven by poor follicle blood flow leaves less room for a vessel signal to matter. No pre-use test identifies that group.
-
Sex: Pattern thinning differs by sex in site and pace. No study reports a different response to this peptide in women and in men.
-
Age: Growth phases shorten with age, so any local signal would meet a smaller follicle. No age-split human data exist for this peptide.
-
Genetic variants: No variant in VEGF, its receptors, or androgen pathways has been tied to a response to sh-Polypeptide-9.
-
Baseline biomarkers: No ferritin, thyroid-hormone, or serum VEGF level has been shown to change regrowth from this peptide. Low iron and thyroid disease cause shedding by other routes.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: adverse events of sh-Polypeptide-9 have not been shown as a human clinical endpoint in more than one trial. Published use is not a controlled adverse-event dataset.
Medium 🟥 🟥
No risk reaches Medium: there is no single controlled trial and no consistent observational series that counts adverse events after this peptide. Harms reported from injected multi-factor blends are not harms measured for this leave-on ingredient.
Low 🟥
Speculative 🟨
Blood-pressure drop at pharmaceutical doses
Intravenous pharmaceutical VEGF-A165 lowered blood pressure during heart-ischemia infusions. Leave-on scalp amounts are not shown to enter blood. The concern is extrapolated from that route, not observed with this cosmetic.
Vessel leak and unwanted new vessels
The parent protein was named for making vessels leak and can feed abnormal vessels, including in psoriasis. No study has measured swelling, new vessels, or plaque flares after this cosmetic peptide.
Immune reaction to a fermented protein
The chain is grown in bacteria, so residual bacterial material could irritate or sensitize skin. Reactions tied specifically to this ingredient are anecdotes, not counted adverse events.
Risk-Modifying Factors
-
Barrier breaks: Microneedling, sunburn, and dermatitis raise the chance a large protein passes the surface. That is the main plausible modifier of exposure.
-
Amount and occlusion: A higher percentage, occlusion (a cover that holds the product on the skin), or a large treated area would raise exposure. Cosmetic formulas are trace; an unstandardized concentrate is unstudied.
-
Psoriasis and active rash: The parent protein can worsen vessel-rich plaques. Inflamed scalp is a higher-risk surface than intact skin.
-
Age: Thinner scalp skin in older adults could increase local passage. This has not been measured for this peptide.
-
Sex: No sex difference in irritation or in any systemic response is reported.
-
Genetic variants: No metabolism variant applies, because the protein is not cleared by CYP enzymes. No receptor variant is known to raise risk.
-
Baseline biomarkers: No blood-pressure reading or serum VEGF level is known to raise irritation or blood exposure from this leave-on peptide.
Key Interactions & Contraindications
-
Minoxidil (topical or low-dose oral): Both are discussed through VEGF. Severity: caution. Consequence: a theoretical add-on to local vessel signals. No interaction study exists, and separating application times is untested.
-
Anti-VEGF antibodies (bevacizumab, ranibizumab): Severity: monitor only during cancer or eye treatment with these drugs. Consequence: opposing actions if the cosmetic reached blood, which is not shown. No dose change is established.
-
Other topical growth-factor serums: Severity: caution. Consequence: stacked vessel signals without a studied combined amount. One product at a time is the only described way to limit that stack.
-
Blood-pressure drugs (amlodipine, losartan): Severity: theoretical caution. Intravenous VEGF-A165 lowered blood pressure; a scalp serum has not. No timing change is evidence-based.
-
Vessel-widening supplements (niacin, inorganic nitrate): Severity: caution, low. Consequence: possible added flushing if the peptide reached blood. No case reports were found.
None of those drug, nonprescription, or supplement pairings is documented in people using this peptide. Each is a mechanism-based caution, not a reported adverse event.
Populations who should avoid sh-Polypeptide-9:
- Active psoriasis, because the parent protein can drive vessels inside plaques
- Sunburn that is still peeling, because the surface barrier is open
- A changing, bleeding, or diagnosed skin cancer in the area to be treated
- Pregnancy and lactation, where no safety data exist for this growth-signal protein
- Children, in whom cosmetic exposure to this protein is unstudied
Risk Mitigation Strategies
-
Intact surface: Application on unbroken scalp, and not on sunburn, psoriasis plaques, or fresh needle channels, limits passage of a vessel-growth protein. That targets leak, unwanted vessels, and theoretical blood exposure.
-
Stay at trace levels: A published multi-factor formula uses about 0.0004–0.002% by weight (US20190134142A1). That gap versus infusion doses is what makes a blood-pressure effect unlikely if the barrier holds.
-
Stop the product if the scalp reacts: Persistent redness, swelling, or itch is the practical signal to discontinue that product. This limits irritation from a fermented protein.
-
Skip suspicious spots: Changing, bleeding, or diagnosed skin cancers are left untreated by this protein, because new-vessel signaling is the harm to avoid there.
Therapeutic Protocol
-
Leave-on serum: Trace sh-Polypeptide-9, about 0.0004–0.002% by weight in one patent blend, once daily on the scalp, usually with other peptides rather than alone (US20190134142A1).
-
Injected blends are separate: Some clinics inject multi-factor solutions into the scalp. Those are not this leave-on peptide and are not presented here as the standard regimen.
-
Who popularized it: No clinic is identified as the source of a sh-Polypeptide-9-only regimen. Multi-peptide serums are brand formulas. Injected blends are promoted by the clinics that sell them.
-
Time of day: No study compares morning with evening. Night application limits rinse-off and is not a tested schedule.
-
Half-life: Intravenous VEGF-A165 had a terminal half-life of 33.7 ± 13 minutes after a 4-hour infusion. Scalp residence of the cosmetic protein is unmeasured, so daily use is custom, not half-life math.
-
Single versus split: No trial compares one daily application with divided doses. Marketed serums use one application a day.
-
Genetic variants: No variant in VEGF, its receptors, or CYP enzymes has been shown to change the amount applied.
-
Sex: No sex-specific amount, response, or adverse-event difference is reported for this peptide.
-
Age: No age-adjusted cosmetic amount is described. Shorter growth phases in later life are hair biology, not a tested dose change.
-
Baseline biomarkers: No blood level, including serum VEGF, is used to set the amount on the scalp.
-
Pre-existing conditions: Psoriasis, peeling sunburn, and open scalp skin are situations in which the parent protein’s vessel-leak effect argues against use.
Discontinuation & Cycling
-
Intended course: Serums are labeled for ongoing cosmetic use, not a fixed course. Nothing shows the peptide must be used for life.
-
Withdrawal: No withdrawal syndrome is described. Circulating parent protein clears in about half an hour; how long it lingers on the scalp is unknown.
-
Taper: No taper is described for a trace topical protein. Stopping is simply stopping.
-
Cycling: Cycling has not been tested. Labels describe continuous use. Any local signal would be expected to fade after stopping, and that expectation is untested.
Sourcing and Quality
-
Name on the label: The identifier to match is sh-Polypeptide-9, the International Nomenclature of Cosmetic Ingredients (INCI, the standard cosmetic name) entry. CG-VEGF is a supplier code for the same sequence, not a second molecule.
-
Fermentation quality: Production is in Escherichia coli. The checks that matter are identity, purity, and residual endotoxin (a fever-triggering bacterial fragment). Retail labels rarely show those results.
-
Third-party testing: Independent seal programs rarely assay this peptide. A certificate of analysis (COA, a batch lab report) is the document that would list purity when a seller provides it.
-
Where it is sold: Large cosmetic hair serums list this INCI name among other peptides. A listing is not evidence of regrowth. Raw-material names include CG-VEGF and SpecPed VEGF.
Practical Considerations
-
Time to effect: No trial gives a timeline. Follicle cycles are measured in months, so comparison photos are often taken near 3–6 months, an interval borrowed from hair biology, not from this peptide.
-
Common pitfall: Assigning a multi-peptide serum’s change to this one ingredient, or expecting minoxidil-like regrowth from a cell letter.
-
Regulatory status: It is a cosmetic ingredient in the United States and the European Union, not an approved drug treatment for hair loss.
-
Cost and access: It is sold in ordinary cosmetic serums, not as a high-cost biologic. Clinic-injected growth-factor courses cost more and are a different product.
Interaction with Foundational Habits
-
Sleep: None. No study links this peptide to sleep depth or to hormones that shift with short sleep. Sleep remains a separate factor in shedding, not an interaction partner.
-
Nutrition: None directly. The peptide does not replace iron or protein that the shaft requires. Shedding from low iron would not be expected to reverse because a topical protein was added.
-
Exercise: None demonstrated. Exercise can raise scalp blood flow by its own route. No study shows that this potentiates or blunts the peptide.
-
Stress management: None demonstrated. Stress-linked shedding is a separate pathway. No study shows an effect on cortisol, or that stress blunts a response to this peptide.
Monitoring Protocol & Defining Success
Before the first application, a useful record is a standardized scalp photograph and, if available, hair density and shaft diameter at one marked site. Blood tests do not track this peptide. Ferritin and thyroid-stimulating hormone matter only as checks for other causes of shedding. No safety panel is validated for leave-on sh-Polypeptide-9, which fits trace cosmetic use and no shown blood level.
The same photograph and density reading are repeated at about 12 weeks and again at about 24 weeks. That spacing follows a follicle growth cycle, not a trial of this peptide. No lab threshold is a reason to stop. Scalp comfort is noted at each application.
Qualitative markers:
- Shedding: hairs lost during washing
- Part width: visible scalp along one fixed part
- Scalp comfort: itch, redness, or swelling after application
- Shaft feel: breakage, as distinct from a change in caliber
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Terminal hair density | No established target; track change from the person’s own baseline | Direct regrowth outcome | Same site, light, and method each time |
| Hair-shaft diameter | No established target; track change from baseline | Caliber loss is part of pattern thinning | Micrometers if a trichometer (a hair-thickness gauge) is used |
| Ferritin | At or above 70 ng/mL | Low iron stores can cause shedding this peptide does not address | Conventional lower limits are often about 15–30 ng/mL |
| Thyroid-stimulating hormone | 0.5–2.5 mIU/L | Thyroid excess or shortage changes shedding | Thyroid-stimulating hormone is the pituitary signal to the thyroid. Conventional upper limits are often near 4–4.5 mIU/L |
Emerging Research
-
No isolated-peptide registration: A ClinicalTrials.gov search on 2026-09-26 found no study whose intervention is sh-Polypeptide-9 or recombinant VEGF for hair loss. That absence is the main gap.
-
Scalp VEGF under two other topicals: Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia (NCT07502976) (pattern hair loss) is recruiting about 60 adults and will biopsy scalp VEGF. Regrowth that tracks VEGF would support the vessel idea; regrowth without a VEGF rise would weaken it. The gel is not this peptide.
-
Laser plus an unnamed serum: Thulium Laser and Growth Factors for Androgenetic Alopecia (NCT07079657) is recruiting about 30 people. The growth-factor serum is not identified as sh-Polypeptide-9, so a benefit would not isolate this peptide.
-
A result that could weaken the case: Control of hair growth and follicle size by VEGF-mediated angiogenesis found that blocking the protein slowed mouse regrowth. A human blockade study with no change in hair would shrink that rationale. None was found.
-
A result that could strengthen the case: A vehicle-controlled hair-count trial of this peptide alone would replace the cell letter Effects of the biomimetic peptide Sh-Polypeptide 9 (CG-VEGF) on cocultures of human hair follicle dermal papilla cells and microvascular endothelial cells. No such trial is registered.
Conclusion
sh-Polypeptide-9 is a trace cosmetic copy of a human protein that grows capillaries and makes them leak. Hair interest rests on follicles recruiting vessels during growth. That link, in the record reviewed here, stays at cells and mice. No human study has counted hairs after the peptide alone, so regrowth is speculative, and skin-conditioning claims sit outside the hair question. Irritation, psoriasis flare-ups, and unwanted vessels are plausible from the biology and are not measured outcomes of the cosmetic.
The intravenous form of the parent protein can drop blood pressure, but that is a high, short infusion, not a leave-on serum. A molecule this large is not known to cross intact scalp skin. The only paper that tests the cosmetic peptide includes a company author, the infusion data come from the drug’s manufacturer, and sellers market a hair use. Insurers have little reason to study a cosmetic serum and a reason not to pay for costly clinic injections of other growth-factor blends, which are a different intervention.
For an adult focused on long-term health, this is a skin-conditioning ingredient carried by a real follicle-vessel mechanism and sold in ordinary multi-peptide serums. It is not a hair drug with a quantified benefit, and it has no documented rate of side effects. The matching reading is a narrow, industry-touched lab signal and a wide gap where hair counts and harms would sit.